Clinical Trials

45 results for Prostate Cancer


Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Study ID: NCT02861573
View Trial

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

  • Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
  • Study ID: NCT03678025
View Trial

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

  • Condition: Prostate Cancer Metastatic
  • Study ID: NCT03655886
View Trial

High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency

  • Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
  • Intervention: Drug: Testosterone Enanthate
  • Study ID: NCT03522064
View Trial

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
  • Study ID: NCT03574571
View Trial

Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT03230734
View Trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT03874884
View Trial

A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Pembrolizumab
  • Study ID: NCT04104893
View Trial

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostatic Cancer
  • Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
  • Study ID: NCT03903835
View Trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: REGN5678, Drug: Cemiplimab
  • Study ID: NCT03972657
View Trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04506567
View Trial

Early Detection of Prostate Cancer by Liquid Biopsy

  • Condition: Prostate Cancer
  • Study ID: NCT04556916
View Trial

Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment

  • Condition: Prostate Cancer, Metastatic Prostate Cancer
  • Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
  • Study ID: NCT03763253
View Trial

A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Stage IV Prostate Cancer
  • Study ID: NCT05189457
View Trial

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Study ID: NCT04868604
View Trial

A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT05075577
View Trial

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04421222
View Trial

SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy.

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Study ID: NCT05983198
View Trial

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT05803941
View Trial

A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostat

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT06052306
View Trial

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04946370
View Trial

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC
  • Study ID: NCT05340374
View Trial

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer
  • Study ID: NCT05383079
View Trial

A Phase I/II Study of Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

  • Condition: Cancer Of Prostate, Prostate Neoplasms
  • Study ID: NCT04633252
View Trial

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hor

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
  • Study ID: NCT06136650
View Trial

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-b

  • Condition: Prostate Cancer Metastatic
  • Study ID: NCT06136624
View Trial

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT06136598
View Trial

A First-in-Human, Phase I PET Imaging Study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients With Advanced Solid Tumor Malignancies

  • Condition: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT04927663
View Trial

A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Genitourinary Malignancies

  • Condition: Prostate Cancer, Renal Cancer, Urethral Cancer
  • Study ID: NCT05888532
View Trial

A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects With Advanced Tumors Who Failed Prior Standard Therapies

  • Condition: Advanced Solid Tumor, Solid Neoplasm
  • Study ID: NCT04662580
View Trial

A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

  • Condition: Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer
  • Study ID: NCT04335682
View Trial

A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors

  • Condition: Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
  • Study ID: NCT05293496
View Trial

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

  • Condition: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castr
  • Study ID: NCT05113537
View Trial

A Phase 1/2 Study of ONCT-534 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT05917470
View Trial

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT06318273
View Trial

A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
  • Study ID: NCT05011188
View Trial

A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate Cancer

  • Condition: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
  • Study ID: NCT06235099
View Trial

A Multi-stage Study to Improve Informed Decision-making for Precision Oncology in Veterans With Advanced Prostate Cancer

  • Condition: Prostate Cancer, Advanced Prostate Carcinoma
  • Study ID: NCT05396872
View Trial

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
  • Study ID: NCT05519449
View Trial

A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
  • Study ID: NCT05766371
View Trial

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT06228053
View Trial

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

  • Condition: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT04071236
View Trial

Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib Who Have Received Prior Anti-Androgen Therapy

  • Condition: Prostate Cancer
  • Study ID: NCT04631744
View Trial

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

  • Condition: Castration-resistant Prostate Cancer, Metastatic Cancer
  • Study ID: NCT05502315
View Trial

A Phase Ib Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT05613894
View Trial